

# Eduardo M Castañedo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11702295/publications.pdf>

Version: 2024-02-01

41  
papers

3,922  
citations

201674

27  
h-index

315739

38  
g-index

41  
all docs

41  
docs citations

41  
times ranked

4610  
citing authors

#	ARTICLE	IF	CITATIONS
1	$\beta$ -sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: Implications for Alzheimer's therapy. <i>Nature Medicine</i> , 1998, 4, 822-826.	30.7	831
2	Amyloid beta peptides in human plasma and tissues and their significance for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2009, 5, 18-29.	0.8	322
3	The $\beta$ -Helical to $\beta$ -Strand Transition in the Amino-terminal Fragment of the Amyloid $\beta$ -Peptide Modulates Amyloid Formation. <i>Journal of Biological Chemistry</i> , 1995, 270, 3063-3067.	3.4	298
4	In vitro formation of amyloid fibrils from two synthetic peptides of different lengths homologous to alzheimer's disease $\beta$ -protein. <i>Biochemical and Biophysical Research Communications</i> , 1986, 141, 782-789.	2.1	239
5	Degradation of soluble amyloid beta-peptides 1-40, 1-42, and the Dutch variant 1-40Q by insulin degrading enzyme from Alzheimer disease and control brains. <i>Neurochemical Research</i> , 2000, 25, 247-255.	3.3	220
6	Amyloid- $\beta$ Peptide Remnants in AN-1792-Immunized Alzheimer's Disease Patients. <i>American Journal of Pathology</i> , 2006, 169, 1048-1063.	3.8	196
7	Comparative proteomics of cerebrospinal fluid in neuropathologically-confirmed Alzheimer's disease and non-demented elderly subjects. <i>Neurological Research</i> , 2006, 28, 155-163.	1.3	188
8	Atherosclerosis, vascular amyloidosis and brain hypoperfusion in the pathogenesis of sporadic Alzheimer's disease. <i>Neurological Research</i> , 2004, 26, 525-539.	1.3	154
9	Fibrillogenesis of synthetic amyloid- $\beta$ peptides is dependent on their initial secondary structure. <i>Neuroscience Letters</i> , 1995, 200, 105-108.	2.1	144
10	Insulin-Degrading Enzyme Sorting in Exosomes: A Secretory Pathway for a Key Brain Amyloid- $\beta$ Degrading Protease. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 79-95.	2.6	126
11	The conformation of Alzheimer's $\beta$ peptide determines the rate of amyloid formation and its resistance to proteolysis. <i>Biochemical Journal</i> , 1996, 314, 701-707.	3.7	120
12	The length of Amyloid- $\beta$ in Hereditary Cerebral Hemorrhage with Amyloidosis, Dutch Type. <i>Journal of Biological Chemistry</i> , 1996, 271, 32185-32191.	3.4	86
13	Different processing of Alzheimer's $\beta$ -protein precursor in the vessel wall of patients with hereditary cerebral hemorrhage with amyloidosis-Dutch type. <i>Biochemical and Biophysical Research Communications</i> , 1988, 151, 1150-1155.	2.1	84
14	Differential Degradation of Amyloid $\beta$ Genetic Variants Associated with Hereditary Dementia or Stroke by Insulin-degrading Enzyme. <i>Journal of Biological Chemistry</i> , 2003, 278, 23221-23226.	3.4	75
15	Plaque-Associated Overexpression of Insulin-Degrading Enzyme in the Cerebral Cortex of Aged Transgenic Tg2576 Mice With Alzheimer Pathology. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 976-987.	1.7	67
16	Alzheimer's Disease and Non-Demented High Pathology Control Nonagenarians: Comparing and Contrasting the Biochemistry of Cognitively Successful Aging. <i>PLoS ONE</i> , 2011, 6, e27291.	2.5	65
17	Insulin-degrading Enzyme in Brain Microvessels. <i>Journal of Biological Chemistry</i> , 2004, 279, 56004-56013.	3.4	62
18	Histopathological and molecular heterogeneity among individuals with dementia associated with Presenilin mutations. <i>Molecular Neurodegeneration</i> , 2008, 3, 20.	10.8	55

#	ARTICLE	IF	CITATIONS
19	Apolipoprotein E increases the fibrillogenic potential of synthetic peptides derived from Alzheimer's, Gelsolin and AA amyloids. <i>FEBS Letters</i> , 1995, 371, 110-114.	2.8	50
20	Chemical characterization of pro-inflammatory amyloid-beta peptides in human atherosclerotic lesions and platelets. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2011, 1812, 1508-1514.	3.8	48
21	Alzheimer disease periventricular white matter lesions exhibit specific proteomic profile alterations. <i>Neurochemistry International</i> , 2013, 62, 145-156.	3.8	45
22	Detergent resistant membrane-associated IDE in brain tissue and cultured cells: Relevance to A $\beta$ and insulin degradation. <i>Molecular Neurodegeneration</i> , 2008, 3, 22.	10.8	40
23	The biochemical aftermath of anti-amyloid immunotherapy. <i>Molecular Neurodegeneration</i> , 2010, 5, 39.	10.8	38
24	The Catalytic Domain of Insulin-degrading Enzyme Forms a Denaturant-resistant Complex with Amyloid $\beta$ Peptide. <i>Journal of Biological Chemistry</i> , 2008, 283, 17039-17048.	3.4	34
25	Proteomic Analysis of Alzheimers Disease Cerebrospinal Fluid from Neuropathologically Diagnosed Subjects. <i>Current Alzheimer Research</i> , 2009, 6, 399-406.	1.4	32
26	Transcriptional Regulation of Insulin-degrading Enzyme Modulates Mitochondrial Amyloid $\beta$ (A $\beta$ ) Peptide Catabolism and Functionality. <i>Journal of Biological Chemistry</i> , 2013, 288, 12920-12931.	3.4	31
27	Tg-SwDI Transgenic Mice Exhibit Novel Alterations in A $\beta$ PP Processing, A $\beta$ Degradation, and Resilient Amyloid Angiopathy. <i>American Journal of Pathology</i> , 2008, 173, 483-493.	3.8	30
28	Notch signaling proteins HES-1 and Hey-1 bind to insulin degrading enzyme (IDE) proximal promoter and repress its transcription and activity: Implications for cellular A $\beta$ metabolism. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2012, 1823, 227-235.	4.1	30
29	Altered APP Processing in PDAPP (Val717 $\rightarrow$ Phe) Transgenic Mice Yields Extended-Length A $\beta$ Peptides. <i>Biochemistry</i> , 2005, 44, 13807-13819.	2.5	28
30	Insulin-degrading enzyme degrades amyloid peptides associated with British and Danish familial dementia. <i>Biochemical and Biophysical Research Communications</i> , 2005, 332, 808-816.	2.1	27
31	The irreversible binding of amyloid peptide substrates to insulin-degrading enzyme. <i>Prion</i> , 2008, 2, 51-56.	1.8	26
32	Alzheimer's Disease from the Perspective of the Systemic and Localized Forms of Amyloidosis. <i>Brain Pathology</i> , 1991, 1, 263-271.	4.1	23
33	The degradation of amyloid beta as a therapeutic strategy in Alzheimer's disease and cerebrovascular amyloidoses. <i>Neurochemical Research</i> , 2002, 27, 1387-1399.	3.3	23
34	Presenilin 1 overexpressions in Chinese hamster ovary (CHO) cells decreases the phosphorylation of retinoblastoma protein: relevance for neurodegeneration. <i>Neuroscience Letters</i> , 2002, 326, 9-12.	2.1	19
35	Amyloid $\beta$ Degradation: A Challenging Task for Brain Peptidases. , 2005, 38, 129-145.		18
36	Internalization and resistance to degradation of Alzheimer's A $\beta$ 1-42 at nanomolar concentrations in THP-1 human monocytic cell line. <i>Neuroscience Letters</i> , 1999, 262, 5-8.	2.1	17

#	ARTICLE	IF	CITATIONS
37	Immunoglobulin lambda light chains are the precursors of ureteral localized amyloidosis: a micromethod for extraction of amyloid. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 1997, 4, 253-258.	3.0	14
38	Differential accumulation of soluble amyloid $\beta$ peptides 1-40 and 1-42 in human monocytic and neuroblastoma cell lines. <i>Cell and Tissue Research</i> , 1999, 298, 225-232.	2.9	11
39	Apolipoprotein E and Amyloidogenesis. <i>Novartis Foundation Symposium</i> , 1996, 199, 132-145.	1.1	6
40	Human Amyloidosis and In Vitro Formation of Alzheimer Amyloid Fibrils. <i>Advances in Behavioral Biology</i> , 1987, , 33-44.	0.2	0
41	<i>Biology of Disease.</i> , 1989, , 25-35.		0